Lantheus to present data on PET imaging agents at SNM meeting

05/19/2010 | (free registration)

Lantheus Medical Imaging said it will present initial data from a Phase II trial of its myocardial perfusion PET imaging agent, flurpiridaz F-18, at the upcoming SNM meeting. The company also will present Phase I results on its LMI1195 cardiac neuronal PET imaging agent.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA